Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,643 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Control Condition Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Single Session Intervention to Prevent Common Mental Disorders and Among College Students

NCT04267068
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Growth Mindset and Modifiable Risk Factor Information, Control
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
17 Years to 26 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Indoor Air Quality and Respiratory Symptoms in Former Smokers

NCT02956213
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
HEPA portable air filter, Sham Control/Active Comparator
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 2, 2026, 1:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-453, Daratumumab, Dexamethasone, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Not applicable Interventional

CBT Depression Intervention for Co-Occurring Chronic Headache

NCT02870725
View directory record Official record
Conditions
Depression, Headaches Chronic, Migraine Disorders
Interventions
CBT Individual Psychotherapy
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Athens, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 2, 2026, 1:55 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

NCT04908189
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
24
States / cities
Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Self-Management Models to Reduce Health Disparities

NCT01221090
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
PDA, CDSMP, PDA/CDSMP
Behavioral
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Sep 2, 2026, 1:55 AM EDT
Terminated Phase 1Phase 2 Interventional

TRF-1101 Assessment in Sickle Cell Disease

NCT00773890
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TRF-1101, Placebo
Drug
Lead sponsor
TRF Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2009 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

NCT01868997
View directory record Official record
Conditions
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions
teprotumumab, normal saline
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Sep 2, 2026, 1:55 AM EDT
Terminated Not applicable Interventional

Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

NCT00152620
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Dexamethasone, Methylprednisolone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 2, 2026, 1:55 AM EDT
Active, not recruiting Not applicable Interventional

Impact of Different Exercise Programs on Knee OA

NCT05844124
View directory record Official record
Conditions
Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking)
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 2, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Exercise to Improve Brain Health in Older African Americans

NCT05597124
View directory record Official record
Conditions
Aging, Alzheimer Disease, Healthy Aging, Cognitive Change
Interventions
Cardio-Dance Fitness, Strength, Flexibility & Balance
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
60 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 2, 2026, 1:55 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

NCT03246685
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Imprime PGG, Pembrolizumab
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

NCT02431468
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

NCT03241368
View directory record Official record
Conditions
Crohn Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 2 Interventional

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

NCT00000891
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

NCT02766374
View directory record Official record
Conditions
Asthma
Interventions
Heart rate variability biofeedback, Placebo
Behavioral
Lead sponsor
Fred Wamboldt, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
2
States / cities
Denver, Colorado • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Sep 2, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

Transitional Intervention for Hyperacusis in Autism

NCT07798297
View directory record Official record
Conditions
Loudness Hyperacusis, Autism Spectrum Disorder (ASD), Hyperacusis
Interventions
Transitional Intervention for Hyperacusis in Autism
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 39 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

NCT02286635
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deflazacort and rifampin, Deflazacort and Clarithromycin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 2, 2026, 1:55 AM EDT
Recruiting Not applicable Interventional

Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

NCT05295615
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ECHS AD Device
Device
Lead sponsor
Herrick Medical LLC
Industry
Eligibility
50 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 2, 2026, 1:55 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 2, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease

NCT00552474
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Loma Linda, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 2, 2026, 1:55 AM EDT
Recruiting No phase listed Observational

Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF

NCT06849752
View directory record Official record
Conditions
Heart Failure, Socioeconomic Adversity
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 1:55 AM EDT